We describe the results of an extremely deep, 0.28 deg 2 survey for z ¼ 3:1 Ly emission-line galaxies in the Extended Chandra Deep FieldYSouth. By using a narrowband 5000 8 filter and complementary broadband photometry from the MUSYC survey, we identify a statistically complete sample of 162 galaxies with monochromatic fluxes brighter than 1:5 ; 10 À17 ergs cm À2 s À1 and observer's frame equivalent widths greater than 80 8. We show that the equivalent width distribution of these objects follows an exponential with a rest-frame scale length of w 0 ¼ 76In addition, we show that in the emission line, the luminosity function of Ly galaxies has a faint-end power-law slope of ¼ À1:49 þ0:45 À0:34 , a bright-end cutoff of log L Ã ¼ 42:64 þ0:26 À0:15 , and a space density above our detection thresholds of (1:46 AE 0:12) ; 10 À3 h 3 70 galaxies Mpc À3 . Finally, by comparing the emission-line and continuum properties of the Ly emitters, we show that the star formation rates derived from Ly are $3 times lower than those inferred from the rest-frame UV continuum. We use this offset to deduce the existence of a small amount of internal extinction within the host galaxies. This extinction, coupled with the lack of extremely high equivalent width emitters, argues that these galaxies are not primordial Population III objects, although they are young and relatively chemically unevolved.

No abstract

SummaryTwenty-one cardiothoracic surgical patients have been treated with fibrin as a topical hemostatic/sealing agent, prepared from bovine fibrinogen clotted with bovine thrombin. Serum samples have been collected before treatment with fibrin and postoperatively between 1 and 9 days, 3 and 12 weeks, and 6 and 8 months. The titers of anti-bovine fibrinogen antibodies, measured by ELISA specific for immunoglobulins IgG or IgM, increased to maximal values after about 8 or 6 weeks, respectively. After 8 months, IgG titers were on average 20-fold lower than the mean maximal value, while IgM titers returned to the normal range. IgG was the predominant anti-bovine fibrinogen immunoglobulin as documented by ELISA, affinity chromatography and electrophoresis. Anti-bovine fibrinogen antibodies present in patients reacted readily with bovine fibrinogen, but did not cross-react with human fibrinogen as measured by ELISA or by immunoelectrophoresis. A significant amount of antibodies against bovine thrombin and factor V has been found, many cross-reacting with the human counterparts. No hemorrhagic or thrombotic complications, or clinically significant allergic reactions, occurred in any patient, in spite of antibody presence against some bovine and human coagulation factors. The treatment of patients with bovine fibrin, without induction of immunologic response against human fibrinogen, appeared to be an effective topical hemostatic/sealing measure.

No abstract

No abstract